Neumora Therapeutics NMRA
NASDAQ NMRA
$0.47 +0.01 (+1.37%)
At close: Nov 11, 2026 · 4:00 PM EST

Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2025)

Updated

Neumora Therapeutics (NMRA) posted Asset Writedowns and Impairment of $217,000 for Q4 2025.

Analysis

Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2025) Analysis & Trends

For FY2025, Neumora Therapeutics' Asset Writedowns and Impairment came in at $595,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neumora Therapeutics 88.31 Mn -529.65 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 217,000.00
API Access

Neumora Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=NMRA&period=max&api_key=YOUR_API_KEY